Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2014
02/20/2014US20140051644 Pharmaceutical composition for treating hyperproliferative diseases
02/20/2014US20140051642 Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
02/20/2014US20140051634 Pharmaceutical combined preparation containing a therapeutic protein
02/20/2014US20140051629 Modulators of the gpr119 receptor and the treatment of disorders related thereto
02/20/2014US20140051625 Bone Targeted Therapeutics and Methods of Making and Using the Same
02/20/2014US20140051624 Oxidant resistant apolipoprotein a-1 and mimetic peptides
02/20/2014US20140051623 Bisphosphonate-Prodrugs
02/20/2014US20140051166 Method and medicament for inhibiting the expression of a given gene
02/20/2014US20140050810 Anti-obesity composition comprising lycium chinensis leaf extract and betaine as active ingredient
02/20/2014US20140050808 Stabilized formulation comprising omega-3 fatty acids and use of the fatty acids for skin care and/or wound care
02/20/2014US20140050807 Compositions containing omega-3 oil with an anti-inflammatory agent and uses thereof
02/20/2014US20140050805 Composition, glucose metabolism-improving agent, and method for improving glucose metabolism
02/20/2014US20140050804 Cold infusion process for fortifying corn and/or soybeans
02/20/2014US20140050803 Compositions and methods for treatment of melanoma
02/20/2014US20140050802 Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects
02/20/2014US20140050799 Risperidone sustained release microsphere composition
02/20/2014US20140050798 Sustained-release nanoparticle compositions and methods using the same
02/20/2014US20140050797 Drug delivery systems comprising solid solutions of wealkly basic drugs
02/20/2014US20140050796 Composition comprising a mixture of dextro- and levo- amphetamines complexed with ion-exchange resin particles to form drug resin particles
02/20/2014US20140050795 Binder powders
02/20/2014US20140050794 Pharmaceutical composition for use as a contraceptive
02/20/2014US20140050793 Novel Compositions for Inhibiting Virus Entry and Promoting Virolysis, and Methods Thereof
02/20/2014US20140050792 Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
02/20/2014US20140050790 Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel
02/20/2014US20140050789 Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
02/20/2014US20140050787 Pharmaceutical compositions resistant to abuse
02/20/2014US20140050786 Combination of triazine derivatives and insulin sensitisers
02/20/2014US20140050785 Dissolution properties of drug products containing olmesartan medoxomil
02/20/2014US20140050784 Pharmaceutical compositions of memantine
02/20/2014US20140050783 Methods and compositions for sleep disorders and other disorders
02/20/2014US20140050779 Transglutaminase-2 inhibitors and uses thereof
02/20/2014US20140050776 Novel method for preventing or treating m tuberculosis infection
02/20/2014US20140050775 Polyamine Derivatives
02/20/2014US20140050772 Methods for treating conditions of the nail unit
02/20/2014US20140050767 Epidermal cooling
02/20/2014US20140050740 Compositions and methods for the treatment of tissue fibrosis
02/20/2014US20140050734 Antibodies against the s100p protein for the treatment and diagnosis of cancer
02/20/2014US20140050729 Methods for treatment of polyposis
02/20/2014US20140050728 Methods and compositions for inhibiting cyclophilin d for the treatment and prevention of obesity and kidney indications
02/20/2014US20140050724 Compositions and Methods
02/20/2014US20140050721 Antineoplastic Combinations with mTOR Inhibitor, Trastuzumab and/or HKI-272
02/20/2014US20140050717 Methods for Treating Bleeding Disorders
02/20/2014US20140050714 Use of hsp70 as a regulator of enzymatic activity
02/20/2014US20140050712 Disorders implicating pufa oxidation
02/20/2014US20140050711 Production of red blood cells and platelets from stem cells
02/20/2014US20140050707 Mir-150 for the treatment of blood disorders
02/20/2014US20140050702 Compositions and Methods for Reducing Blood Alcohol Content
02/20/2014US20140050699 Heterocyclic inhibitors of glutaminase
02/20/2014US20140050696 Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use
02/20/2014US20140050695 Hepatitis C Virus Inhibitors
02/20/2014US20140050694 Method of Treating Transplant Rejection and Autoimmune Diseases
02/20/2014US20140050692 Polyesters and methods of use thereof
02/20/2014US20140050690 Nanoparticle containing prostaglandin i 2 derivative
02/20/2014US20140050680 Dapsone to treat rosacea
02/20/2014US20140050677 Personal care and medicinal products incorporating bound organosulfur groups
02/20/2014US20140050675 Antioxidant compositions for soft oral tissue and methods of formulation and use thereof
02/20/2014US20140050672 Epidermal cooling
02/20/2014US20140050665 Method for the treatment or prophylaxis of lymphangioleiomyomatosis (lam) and animal model for use in lam research
02/20/2014DE102012214540A1 Zahnfüllungsmaterialien und Zahnlacke zur Hemmung der Biofilmbildung von Streptococcus mutans und deren Herstellung Dental filling materials and tooth coatings to inhibit biofilm formation of Streptococcus mutans and their preparation
02/20/2014DE102012016908A1 Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung Tris (hetero) aryl pyrazoles and their use
02/20/2014CA2876459A1 Imidazo[2,1]thiazol-3-one derivatives useful as diagnostic agents for alzheimer's disease
02/19/2014EP2698637A1 Marker for determination of sensitivity to anti-cancer agent
02/19/2014EP2698375A2 TGR5 modulators and method of use thereof
02/19/2014EP2698372A1 Novel imidazo-oxazine compound or salt thereof
02/19/2014EP2698371A1 Novel anti-platelet compound addition salt
02/19/2014EP2698370A2 3-substituted-4-oxo-3,4-dihydro-imidazo-[5,1-d][1,2,3,5]-tetrazine-8-carboxylic acid amides as anticancer agents
02/19/2014EP2698369A1 Benzopyrone derivative and use thereof
02/19/2014EP2698368A1 Novel pyrazole derivative
02/19/2014EP2698367A1 Benzimidazoles for the treatment of cancer
02/19/2014EP2698168A1 Paliperidone Oral Solution
02/19/2014EP2698167A2 Dosage form of an estriol and glatiramer acetate polymer-1 for the treatment of multiple sclerosis
02/19/2014EP2698161A1 Composition, glucose metabolism-improving agent, and method for improving glucose metabolism
02/19/2014EP2698160A2 Organic compounds
02/19/2014EP2698159A1 Pitavastatin-containing preparation and method for producing same
02/19/2014EP2698158A1 Immunomodulation by IAP Inhibitors
02/19/2014EP2698157A1 Method of treatment using fatty acid synthesis inhibitors
02/19/2014EP2698156A1 Phenylbutyric acid for chemoprevention
02/19/2014EP2698155A1 Pharmaceutical unit dosage form comprising 4-phenylbutyric acid
02/19/2014EP2698154A1 S1P receptor modulators for treating multiple sclerosis
02/19/2014EP2698153A1 Prevention and treatment of oxidative stress disorders by compounds which elevate intracellular levels of glutathione or phase II detoxification enzymes
02/19/2014EP2698152A1 Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative
02/19/2014EP2698151A1 Orally Disintegrating Formulation of Paliperidone
02/19/2014EP2698150A1 Oral solid preparation of compound antituberculosis drug and preparation method thereof
02/19/2014EP2698149A1 Topical Aqueous Pharmaceutical Compositions of Flurbiprofen and Chlorhexidine
02/19/2014EP2698148A1 Chewing Gum Formulations Comprising Dapoxetine and Tadalafil
02/19/2014EP2698147A1 Oral Film Formulations Comprising Dapoxetine and Tadalafil
02/19/2014EP2698146A1 Tablet Formulations Comprising Tadalafil and Dapoxetine
02/19/2014EP2698145A1 Pharmaceutical Formulations comprising dapoxetine and a PDE5 inhibitor
02/19/2014EP2698144A1 Prolonged release gabapentin tablet formulation whose ability to stay in the stomach is improved
02/19/2014EP2698062A1 Inhibitors of poly(adp-ribose)polymerase
02/19/2014EP2697386A2 Pepducin design and use
02/19/2014EP2697265A1 Polysaccharides comprising two antithrombin iii-binding sites, preparation thereof and use thereof as antithrombotic medicaments
02/19/2014EP2697241A2 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
02/19/2014EP2697240A1 Glycoside derivatives and uses thereof
02/19/2014EP2697238A2 Solid forms of antiretroviral compounds, process for the preparation and their pharmaceutical composition thereof
02/19/2014EP2697233A1 Macrocyclic triazine compounds for the treatment of hepatitis c
02/19/2014EP2697232A1 6,7 - dihydroimidazo [2, 1 - b][1, 3]oxazine bactericides
02/19/2014EP2697230A1 Compounds for the treatment of hepatitis c
02/19/2014EP2697229A2 Antimicrobial compounds and methods of making and using the same
02/19/2014EP2697228A1 Cgrp receptor antagonists
1 ... 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 ... 7860